A TROP2/Claudin Program Mediates Immune Exclusion to Impede Checkpoint Blockade in Breast Cancer

This study identifies a TROP2-Claudin 7-mediated barrier mechanism that excludes T cells and impedes immunotherapy in triple-negative breast cancer, demonstrating that targeting TROP2 disrupts tight junctions to restore immune infiltration and enhance checkpoint blockade efficacy.

The Gist

The Big Picture: Why Some Cancers Hide from the Immune System

Imagine your body's immune system as a highly trained police force. Their job is to patrol the city (your body), find criminals (cancer cells), and arrest them.

In some types of cancer, specifically a tough kind called Triple-Negative Breast Cancer (TNBC), the criminals are very good at hiding. They build a fortress that the police can't get through. This is called "immune exclusion." The police are standing outside the walls, shouting, but they can't get inside to do their job.

This study discovered who is the architect of that fortress and how to knock down the walls.

---

The Villain: TROP2 (The "Wall Builder")

The researchers found that a protein called TROP2 is the mastermind behind this fortress.

• What it does: TROP2 acts like a construction foreman that orders the cancer cells to build a super-tight, impenetrable wall around themselves.
• The Wall: This wall is made of "tight junctions" (think of them as super-strong mortar between bricks). One specific type of brick in this wall is called Claudin 7. TROP2 holds these bricks together so tightly that even the smallest police officer (a T-cell) cannot squeeze through.
• The Result: Because the wall is so strong, the immune system stays outside. The cancer grows unchecked, and drugs designed to wake up the immune system (like immunotherapy) fail because the police can't reach the enemy.

The Analogy: Imagine a bank robber (the cancer) wearing a suit of armor (TROP2). This armor has a special feature: it glues the doors and windows shut (Claudin 7). No matter how loud the police (immune system) shout, they can't get in to arrest the robber.

The Discovery: How They Figured It Out

The scientists looked at tumors from patients and compared two groups:

1. "Hot" Tumors: These had lots of police (immune cells) inside. They responded well to treatment.
2. "Cold" Tumors: These had almost no police inside. They were resistant to treatment.

They found that the "Cold" tumors were full of TROP2. The more TROP2 there was, the stronger the wall, and the fewer police could get inside.

The Twist: It's Not About "Signaling," It's About "Glue"

For a long time, scientists thought TROP2 helped cancer grow by sending "growth signals" (like a radio message telling the cell to multiply).

This study proved that's not the main story here.
The researchers removed the "radio antenna" (the inside part of the TROP2 protein) but left the "glue" part (the outside part) intact.

• Result: The cancer cells still built the wall and still kept the police out.
• Conclusion: TROP2's main job in this context isn't sending messages; it's physically gluing the cells together to block the immune system.

The Solution: Breaking the Wall

The researchers tested a drug called Sacituzumab govitecan (SG). This is a famous "Antibody-Drug Conjugate" (ADC) used to treat breast cancer. It has two parts:

1. A hook (an antibody) that grabs onto TROP2.
2. A bomb (a chemotherapy drug) that kills the cell.

The Experiment:
They used a version of the drug that only had the hook (no bomb) and combined it with a drug that wakes up the police (anti-PD1 immunotherapy).

• Step 1: The hook grabbed TROP2. This broke the "glue" (disrupted the tight junctions).
• Step 2: The wall fell down. The police (T-cells) could finally rush inside.
• Step 3: Once inside, the "wake up" drug (anti-PD1) told the police to attack.

The Result: The combination worked incredibly well. By breaking the wall (targeting TROP2) and waking up the police (immunotherapy), they defeated the cancer.

Why This Matters for Patients

1. Predicting Success: If a patient's tumor has high levels of TROP2, they are likely to fail standard immunotherapy because the police can't get in. Doctors can now use TROP2 levels as a "warning sign."
2. New Strategy: Instead of just trying to wake up the immune system, we need to demolish the wall first.
3. The Future: This explains why the combination of Sacituzumab govitecan + Immunotherapy is working so well in clinical trials. It's not just about the chemotherapy killing cells; it's about the antibody breaking the barrier so the immune system can finish the job.

Summary in One Sentence

This study found that a protein called TROP2 builds a physical wall around breast cancer cells to keep the immune system out, but using a drug to break that wall allows immunotherapy to finally work.

Technical Summary

1. Problem Statement

Triple-negative breast cancer (TNBC) is an aggressive subtype with poor prognosis. While some TNBCs are "immune-hot" (rich in tumor-infiltrating lymphocytes) and respond to immune checkpoint blockade (ICB), others are "immune-cold" and resistant to both chemotherapy and immunotherapy. The molecular mechanisms driving this "immune exclusion"—where T cells are physically barred from entering the tumor core—remain poorly defined. Additionally, TROP2 (Trophoblast Cell-Surface Antigen 2) is a validated target for antibody-drug conjugates (ADCs) like Sacituzumab govitecan (SG), but its functional role beyond drug delivery (specifically regarding immune modulation) is unclear.

2. Methodology

The study employed a multi-modal approach combining human clinical data analysis, spatial transcriptomics, and rigorous in vivo and in vitro mouse models:

• Spatial Transcriptomics: Researchers analyzed 88 regions of interest (ROIs) from 8 treatment-naïve human TNBC specimens using the GeoMx Digital Spatial Profiler (DSP). They compared gene expression in "immune-hot" (high CD8+ density) vs. "immune-cold" (low CD8+ density) tumor and fibroblast compartments.
• Bioinformatic Integration: Findings were cross-referenced with clinical datasets of TNBC patients treated with ICB (Pembrolizumab) to identify genes consistently associated with non-response. Gene Set Variation Analysis (GSVA) and TIMER deconvolution were used to correlate TROP2 expression with immune signatures.
• Genetic Manipulation in Mouse Models:
  • CRISPR-Cas9: Endogenous TROP2 was knocked out (KO) in murine TNBC cell lines (4T1 and AT-3).
  • Reconstitution: TROP2-KO cells were reconstituted with full-length murine TROP2, a truncated mutant lacking the intracellular domain (TROP2-ECDTM), or human TROP2 (hTROP2) to test domain-specific functions.
  • Knockdown: Claudin 7 (Cldn7) was knocked down via shRNA to mimic TROP2 loss.
• In Vivo Therapeutic Studies: Immunocompetent (BALB/c) and immunodeficient (Nude/NSG) mice were injected with engineered tumors. Treatments included:
  • Anti-PD1 antibodies.
  • hRS7 (the naked antibody component of Sacituzumab govitecan).
  • Combination therapy (hRS7 + Anti-PD1).
  • CD8+ T cell depletion to verify immune dependence.
• Molecular Analysis: Co-immunoprecipitation (Co-IP), immunofluorescence (IF), immunohistochemistry (IHC), and RNA-seq were used to assess protein interactions (TROP2-Claudin 7), tight junction integrity, and T cell infiltration/activation status.
• Clinical Validation: Retrospective analysis of RNA-seq data from patients treated with anti-PD1 therapy to correlate TROP2 expression with treatment response (Odds Ratios) and T cell clonotype expansion.

3. Key Contributions

• Discovery of a Barrier Mechanism: The study identifies TROP2 as a master regulator of barrier-mediated immune exclusion in TNBC, distinct from its previously known intracellular signaling roles.
• Mechanism Elucidation: It establishes that TROP2 physically interacts with Claudin 7 to maintain tight junction integrity. This creates a mechanical barrier that prevents CD8+ T cell infiltration.
• Domain Independence: The study proves that the intracellular domain (ICD) of TROP2 is dispensable for immune exclusion; the extracellular and transmembrane domains alone are sufficient to bind Claudin 7 and enforce the barrier.
• Therapeutic Synergy: It provides a mechanistic rationale for combining TROP2-targeting antibodies with PD-1 blockade, showing that disrupting the physical barrier (via TROP2 targeting) is required to allow T cells to access the tumor, while PD-1 blockade is required to activate them.

4. Key Results

• TROP2 Correlates with Immune Exclusion: Spatial transcriptomics revealed that TROP2 (along with Claudin 1 and 7) is highly expressed in immune-cold TNBC tumor cells. High TROP2 expression is inversely correlated with T cell infiltration and predicts poor survival and lack of response to ICB in human cohorts.
• TROP2 Drives Tumor Growth via Immune Evasion:
  • TROP2-KO tumors grew significantly slower than wild-type (WT) tumors in immunocompetent mice but showed no growth defect in immunodeficient mice.
  • Depletion of CD8+ T cells abolished the growth difference between WT and KO tumors, confirming the effect is CD8-dependent.
  • TROP2-KO tumors exhibited massive infiltration of activated, effector-memory CD8+ T cells (PD1+, Granzyme B+).
• TROP2-Claudin 7 Interaction:
  • TROP2 physically binds to Claudin 7. Loss of TROP2 leads to the downregulation and mislocalization of Claudin 7 and Occludin, disrupting tight junctions.
  • Reconstitution of TROP2-KO cells with the TROP2-ECDTM mutant (lacking the ICD) fully restored tight junction integrity, Claudin 7 expression, and the immune-excluded phenotype, proving the ICD is not required for this function.
• Therapeutic Implications:
  • In a humanized TROP2 mouse model, treatment with hRS7 (naked antibody) alone did not shrink tumors (no cytotoxic payload), and Anti-PD1 alone had limited efficacy.
  • Combination Therapy (hRS7 + Anti-PD1) significantly inhibited tumor growth.
  • Mechanistically, hRS7 treatment disrupted tight junctions (reduced Claudin 7), allowing T cell infiltration. Anti-PD1 then activated these infiltrating cells.
  • Inducible knockdown of Claudin 7 mimicked the effect of hRS7, sensitizing tumors to Anti-PD1.
• Clinical Validation: In human patients treated with Pembrolizumab, high epithelial TROP2 expression was a strong negative predictor of response (Odds Ratio ~0.06). High TROP2 tumors showed T cells in a "naïve" state, whereas low TROP2 tumors showed activated, cytotoxic T cells.

5. Significance

• Paradigm Shift in ADC Understanding: The study suggests that the efficacy of TROP2-targeting ADCs (like Sacituzumab govitecan) may not solely rely on the cytotoxic payload (SN-38) but also on the antibody component's ability to disrupt tight junctions, thereby "unlocking" the tumor to immune attack.
• New Biomarker: TROP2 expression serves as a biomarker for "immune-cold" status and resistance to ICB, suggesting that TROP2-high patients may specifically benefit from combination strategies.
• Therapeutic Strategy: The findings support the clinical strategy of combining TROP2-targeting agents (even naked antibodies or ADCs) with immune checkpoint inhibitors to overcome resistance in TNBC and potentially other TROP2-expressing solid tumors (e.g., lung, ovarian).
• Novel Mechanism of Resistance: It defines a specific, reversible mechanical barrier (tight junctions regulated by TROP2/Claudin 7) as a primary mechanism of immune exclusion, offering a new target for therapeutic intervention beyond traditional immunosuppressive pathways.